1. Walser M: Ion association: VI. Interactions between calcium, magnesium, inorganic phosphate, citrate, and protein in normal human plasma. J.Clin.Invest. 40:723 1961

2. Parfitt AM, Kleerekoper M: Clinical disorders of calcium, phosphorus and magnesium metabolism., in Maxwell MH, Kleeman CR. (eds): Clinical disorders of fluid and electrolyte metabolism, 3rd ed. New York, McGraw-Hill, 1980, pp 947

3. Stewart AF, Broadus AE: Mineral metabolism., in Felig P, Baxter ID, Broadus AE, Frohman LA. (eds): Endocrinology and metabolism, 2nd ed. New York, McGraw-Hill, 1987, pp 1317

4. Bringhurst FR, Demay MB, Kronenberg HM: Hormones and disorders of mineral metabolism., in Wilson JD, Foster DW, Kronenberg HM, Larsen PR. (eds): Williams textbook of endocrinology, 9th ed. Philadelphia, Saunders, 1998, pp 1155

5. Brown EM: Physiology of calcium homeostasis., in Bilezikian JP, Marcus R, Levine MA. (eds): The parathyroids: basic and clinical concepts, 2nd ed. San Diego, Academic Press, 2001, pp 167

6. Fraser DR, Kodicek E: Regulation of 25-hydroxycholecalciferol-1-hydroxylase activity in kidney by parathyroid hormone. Nat.New.Biol. 241:163 1973

7.Potts JT Jr, Jhppner H: Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism, and bone development: the proteins, their genes, and receptors., in Avioli LV, Krane SM. (eds): Metabolic bone disease, 3rd ed. New York, Academic Press, 1997, pp 51

8. Grant FD, Conlin PR, Brown EM: Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J.Clin.Endocrinol.Metab. 71:370 1990

9. Brown EM, Gamba G, Riccardi D, et al: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 366:575 1993

10. Mayer GP, Keaton JA, Hurst JG, et al: Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 104:1778 1979

11. Hanley DA, Ayer LM: Calcium-dependent release of carboxyl-terminal fragments of parathyroid hormone by hyperplastic human parathyroid tissue in vitro. J.Clin.Endocrinol.Metab. 63:1075 1986

12. D'Amour P, Palardy J, Bahsali G, et al: The modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration. J.Clin.Endocrinol.Metab. 74:525 1992

13. Segre GV, D'Amour P, Hultman A, et al: Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J.Clin.Invest. 67:439 1981

14. Yamamoto M, Igarishi T, Muramatsu M, et al: Hypocalcemia increases and hypercalcemia decreases the steady state level of parathyroid hormone messenger RNA in the rat. J.Clin.Invest. 83:1053 1989

15. Naveh-Many T, Silver J: Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J.Clin.Invest. 86:1313 1990

16. Kremer R, Bolivar I, Goltzman D, et al: Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 125:935 1989

16a. Xu M, Choudhary S, Goltzman D, et al: Do cycloxygenase-2 knockout mice have primary hyperparathyroidism? Endocrinology 146:1843. 2005

16b. Dusso A, Cozzolino M, Lu Y, Sato T, Slatopolsky E. 1,25-Dihydroxyvitamin D downregulation of TGF alpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure. J. Steroid Biochem Mol. Biol. 89-90; 507-511, 2004

16c. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al:  The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 117:4003, 2007

17. Chan YL, McKay C, Dye E, et al: The effect of 1,25 dihydroxycholecalciferol on parathyroid hormone secretion by monolayer cultures of bovine parathyroid cells. Calcif.Tiss.Int. 38:27 1986

17a. Goltzman D, Miao D, Panda DK, Hendy GN. Effects of calcium and of the vitamin D system on skeletal and calcium homeostasis: lessons from genetic models. J. Steroid Biochem. Mol. Biol. 89-90:485, 2004.

18. Friedman PA, Gesek FA: Cellular calcium transport in renal epithelia: Measurement, mechanisms, and regulation. Physiol.Rev. 75:429 1995

19. Nordin BE, Peacock M: Role of kidney in regulation of plasma-calcium. Lancet 2:1280 1969

20. Rouse D, Suki WN: Renal control of extracellular calcium. Kidney Int. 38:700 1995

21. Rouleau MF, Warshawsky H, Goltzman D: Parathyroid hormone binding in vivo to renal, hepatic, and skeletal tissues of the rat using a radioautographic approach. Endocrinology 118:919 1986

22. Jhppner H, Abou-Samra AB, Freeman MW, et al: A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254:1024 1991

23. Abou-Samra AB, Jhppner H, Force T, et al: Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol triphosphates and increases intracellular free calcium. Proc.Natl.Acad.Sci.USA 89:2732 1992

24. Amizuka N, Lee HS, Kwan MY, et al: Cell-specific expression of the parathyroid hormone (PTH)/PTH-related peptide receptor gene in kidney from kidney-specific and ubiquitous promoters. Endocrinology 138:469 1997

25. Keusch I, Traebert M, Lotscher M, et al: Parathyroid hormone and dietary phosphate provoke a lysosomal routing of the proximal tubular Na/Pi-cotransporter type II. Kidney Int. 54: 1224 1998

26. Brenza HL, Kimmel-Jehan C, Jehan F, et al: Parathyroid hormone activation of the 25-hydroxyvitamin D3-1a-hydroxylase gene promoter. Proc.Natl.Acad.Sci.USA 95:1387 1998

27. Azarani A, Goltzman D, Orlowski J: Parathyroid hormone and parathyroid hormone-related peptide inhibit the apical Na+/H+ exchanger NHE-3 isoform in renal cells (OK) via a dual signaling cascade involving protein kinase A and C. J.Biol.Chem. 270:20004 1995

28. Derrickson BH, Mandel LJ: Parathyroid hormone inhibits Na(+)-K(+)-ATPase through Gq/G11 and the calcium-independent phospholipase A2. Am.J.Physiol. 272:F781 1997

29. Morel F, Chabardes D, Imbert-Teboul M: Multiple hormonal control of adenylate cyclase in distal segments of the rat kidney. Kidney Int. 11:555 1982

30. De Rouffignac C, Quamme GA: Renal magnesium handling and its hormonal control. Physiol.Rev. 74:305 1994

31. Hebert SC: Extracellular calcium-sensing receptor: Implications for calcium and magnesium handling in the kidney. Kidney Int. 50:2129 1996

31a. Hoenderop JGJ, Nilius B, Bindels RJM. Calcium absorption across epithelia. Physiol Rev. 85:373, 2005.

32. Amizuka N, Karaplis AC, Henderson HE, et al: Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev.Biol. 175:166 1996

33. Rouleau MF, Mitchell J, Goltzman D: In vivo distribution of parathyroid hormone receptors in bone: Evidence that a predominant osseous target cell is not the mature osteoblast. Endocrinology 123:187 1988

34. Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140:3552 1999

35.Takahashi N, Udagawa N, Takami M, et al: Cells of bone: osteoclast generation., in Bilezikian JP, Raisz LG, Rodan GA. (eds): Principles of bone biology, 2nd ed. San Diego, Academic Press, 2002, pp109

36. Tam C, Heersche J, Murray T, et al: Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 110:506 1982

37. McCarthy TL, Centrella M, Canalis E: Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 124:1247 1989

38. Jilka R, Weinstein R, Bellido T: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J.Clin.Invest. 104:439 1999

39. Miao D, He B, Karaplis AC, et al: Parathyroid hormone is essential for normal fetal bone formation. J.Clin.Invest. 109:1173 2002

39a Goltzman D.  Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys. 473:218. 2008

40. Holick MF: Vitamin D: Photobiology, metabolism and clinical applications., in DeGroot L, et al (eds): Endocrinology. Philadelphia, Saunders, 1995, pp 990

41. Bouillon R, Okamura WH, Norman AW: Structure-function relationships in the vitamin D endocrine system. Endo.Revs. 16:200 1995

42. Panda DK, Miao D, Tremblay ML: Targeted ablation of the 25- hydroxyvitamin D 1a-hydroxylase enzyme: Evidence for skeletal, reproductive, and immune dysfunction. Proc.Natl.Acad.Sci.USA 98:7498 2001

43. Hewison M, Zehnder D, Bland R, et al: 1alpha-hydroxylase and the action of vitamin D. J.Mol.Endocrinol. 25(2):141 2000

44. St-Arnaud R, Arabian A, Travers R, et al: Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24, 25-dihydroxyvitamin D. Endocrinology 141:2658 2000

45. Jurutka PW, Whitfield GK, Hsieh JC, et al: Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev.Endocr.Metab.Disord. 2(2):203 2001

46. Favus MF: Intestinal absorption of calcium, magnesium and phosphorus., in Coe FL, Favus MJ. (eds): Disorders of bone and mineral metabolism. New York, Raven, 1992, pp 57

48. Van de Graaf SFJ, Boullart I, Hoenderop JGJ, Bindels RJM. Regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1α,25-dihydroxy Vitamin D3 and dietary Ca2+. J. Steroid Biochem. Molec. Biol. 89-90: 303-308, 2004.

49. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D. Inactivation of the 25-dihydroxyvitamin D-1alpha-hydroxylase and vitamin D receptor demonstrates independent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol Chem. 279:16754, 2004.

49a Benn BS, Ajibade D, Porta A, et al:  Active intestinal calcium transport in the absence of transient receptor potential vanilloid type 6 and calbindin-d9k. Endocrinology. 149:3196 2008

50. Li YC, Pirro, AE, Amling M, et al: Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc.Natl.Acad.Sci.USA. 94:9831 1997

50a  Xue Y, Karaplis AC, Hendy GN, et al  Genetic models show that parathyroid hormone and 1,25-dihydroxyvitamin D3 play distinct and synergistic roles in postnatal mineral ion homeostasis and skeletal development. Hum Mol Genet. 14:1515  2005

51. Stewart AF, Horst R, Deftos LJ, et al: Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and non-humoral groups. N.Engl.J.Med. 303:1377 1980

52. Yasuda T, Banville D, Hendy GN, et al: Characterization of the human parathyroid hormone-like peptide gene. J.Biol.Chem. 264:7720 1989

53. Mangin M, Ikeda K, Dreyer BE, et al: Isolation and characterization of the human parathyroid hormone-like peptide gene. Proc.Natl.Acad.Sci.USA. 86:2408 1989

54. Rabbani SA, Mitchell J, Roy DR, et al: Influence of the amino-terminus on in vitro and in vivo biological activity of synthetic parathyroid hormone and parathyroid hormone-like peptides of malignancy. Endocrinology 123:2709 1988

55. Usdin TB, Hoare SR, Wang T, et al: TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat.Neurosci. 2(11):941 1999

56. Usdin TB, Gruber C, Bonner TI: Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J.Biol.Chem. 270:15455 1995

57. Goltzman D, Hendy GN, Banville D: Parathyroid hormone-like peptide: Molecular characterization and biological properties. Trends Endocrinol.Metab. 1:39 1989

58. Rabbani SA, Haq M, Goltzman D: Biosynthesis and processing of endogenous parathyroid hormone-related peptide (PTHrP) by the rat Leydig cell tumor H-500. Biochemistry 32:4931 1993

59. Plawner LL, Philbrick WM, Burtis WJ, et al: Cell type-specific secretion of parathyroid hormone-related protein via the regulated versus the constitutive secretory pathway. J.Biol.Chem. 270:14078 1995

60. Eto M, Akishita M, Ishikawa M, et al: Cytokine-induced expression of parathyroid hormone-related peptide in cultured human vascular endothelial cells. Biochem.Biophys.Res.Commun. 249:339 1998

61. Kremer R, Karaplis AC, Henderson JE, et al: Regulation of parathyroid hormone-like peptide in cultured normal human keratinocytes. J.Clin.Invest. 87:884 1991

62. Sebag M, Henderson JE, Goltzman D, et al: Regulation of parathyroid hormone-related peptide production in normal human mammary epithelial cells in vitro. Am.J.Physiol. 267:723 1994

63. Casey ML, Mike M, Erk A, et al: Transforming growth factor-B1 stimulation of parathyroid hormone-related protein expression in human uterine cells in culture: mRNA levels and protein secretion. J.Clin.Endocrinol.Metab. 74:950 1992

64. Aklilu F, Park M, Goltzman D, et al: Induction of parathyroid hormone related peptide by the Ras oncogene: Role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy. Cancer Res. 57:4517 1997

65. Kremer R, Sebag M, Champigny C, et al: Identification and characterization of 1,25-dihydroxyvitamin D3-responsive repressor sequences in the rat parathyroid hormone-related peptide gene. J.Biol.Chem. 271:16310 1996

66. Lu C, Ikeda K, Deftos LJ, et al: Glucocorticoid regulation of parathyroid hormone-related peptide gene transcription in a human neuroendocrine cell line. Mol.Endocrinol. 3:2034 1989

67. Liu B, Goltzman D, Rabbani SA: Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. Endocrinology 132:1658 1993

68. Haq M, Kremer R, Goltzman D, et al: A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J.Clin.Invest. 91:2416 1993

69. El Abdaimi K, Papavasiliou V, Rabbani SA, et al: Reversal of hypercalcemia with the vitamin D analog EB1089 in a model of human squamous cancer. Cancer Res. 59:3325 1999

70. Liu B, Goltzman D, Rabbani SA: Processing of pro-PTHrP by the prohormone convertase, furin: Effect on biological activity. Am.J.Physiol. 268:832 1995

71. Liu B, Amizuka N, Goltzman D, et al: Inhibition of processing of parathyroid hormone-related peptide by antisense furin: Effect in vitro and in vivo on rat Leydig (H-500) tumor cells. Int.J.Cancer 63:1 1995

72. Care AD, Abbas SL, Pickard DW, et al: Stimulation of ovine placental transport of calcium and magnesium by mid-molecule fragments of human parathyroid hormone-related protein. Exp.Physiol. 75:605 1990

73. Fenton AJ, Kemp BE, Hammonds RG, et al: A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of PTHrP (107-111). Endocrinology 129:3424 1991

74. Philbrick WM, Dreyer BE, Nakchbandi IA, et al: Parathyroid hormone-related protein is required for tooth eruption. Proc.Natl.Acad.Sci.USA. 95:11846 1998

75. Henderson JE, Amizuka H, Warshawsky H, et al: Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol.Cell.Biol. 15:4064 1995

76. Lam MHC, House CM, Tiganis T, et al: Phosphorylation of the cyclin-dependent kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear localization. J.Biol.Chem. 274:18959 1999

77. Aarts MM, Rix A, Guo J, et al: The nucleolar targeting signal (NTS) of parathyroid hormone-related protein mediates endocytosis and nuclear translocation. J.Bone Miner.Res. 14:1493 1999

78. Meerovitch K, Wing W, Goltzman D: Proparathyroid hormone related protein is associated with the chaperone protein BiP and undergoes proteasome mediated degradation. J.Biol.Chem. 273:21024 1998

79. Nguyen M, He B, Karaplis A: Nuclear forms of parathyroid hormone-related peptide are translated from non-AUG start sites downstream from the initiator methionine. Endocrinology 142:694 2001

80. Kovacs CS, Lanske B, Hunzelman JL, et al: Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor. Proc.Natl.Acad.Sci.USA. 93:15233 1996

81. Takahashi K, Inoue D, Ando K, et al: Parathyroid hormone-related peptide as a locally produced vasorelaxant regulation of its mRNA by hypertension in rats. Biochem.Biophys.Res.Commun. 208:447 1995

82. Morimoto T, Devora GA, Mibe M, et al: Parathyroid hormone-related protein and human myometrial cells: Action and regulation. Mol.Cell.Endocrinol. 129:91 1997

83. Yamamoto M, Harm SC, Grasser WA, et al: Parathyroid hormone-related protein in the rat urinary bladder: A smooth muscle relaxant produced locally in response to mechanical stretch. Proc.Natl.Acad.Sci.USA. 89:5326 1992

84. Wysolmerski JJ, Mccaugherncarucci JF, Daifotis AG, et al: Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development 121:3539 1995

85. Holick MF, Ray S, Chen TC, et al: A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice. Proc.Natl.Acad.Sci.USA. 91:8014 1994

86. Fukayama S, Tashjian AH Jr, Davis JN, et al: Signaling by N- and C-terminal sequences of parathyroid hormone-related protein in hippocampal neurons. Proc.Natl.Acad.Sci.USA. 92:10182 1995

87. Vasavada R, Cavaliere C, D'Ercole AJ, et al: Overexpression of PTHrP in the pancreatic islets of transgenic mice causes hypoglycemia, hyperinsulinemia and islet hyperplasia. J.Biol.Chem 271:1200 1996

88. Karaplis AC, Luz A, Glowacki J, et al: Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev. 8:277 1994

89. Amizuka N, Karaplis AC, Henderson JE, et al: Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev.Biol. 175:166 1996

90. Lanske B, Amling M, Neff L, et al: Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J.Clin.Invest. 104:399 1999

91.Zhang P, Jobert AS, Couvineau A, et al: A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J.Clin.Endocrinol.Metab. 83:3373 1998

92. Karaplis AC, Bin He MT, Nguyen A, et al: Inactivating mutation in the human parathyroid hormone receptor type I gene in Blomstrand chondrodysplasia. Endocrinology 139:5255 1998

92a Miao D, He B, Jiang Y, et al : Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest. 115 :2402 2005.

92b. Miao D, Li J, Xue Y, et al: Parathyroid hormone-related peptide is required for increased trabecular bone mass in parathyroid hormone-null mice. Endocrinology 145:3554, 2004.

93. Mundy GR: Bone remodeling., in Favus MJ. (ed): Primer on the metabolic bone diseases and disorders of mineral metabolism, fourth edition. Philadelphia, Lippincott, Williams and Wilkens, 1999, pp 30

94. Milne M, Kang MI, Cardona G, et al: Expression of multiple thyroid hormone receptor isoforms in rat femoral and vertebral bone and in bone marrow osteogenic cultures. J.Cell Biochem. 74:684 1999

95. Fell HB, Mellanby E: The effect of hypervitaminosis A on embryonic limb bones cultured in vitro. J.Physiol. 116:320 1952

96. Horowitz MC Lorenzo JA: Local regulators of bone., in Bilezikian JP, Raisz LG, Rodan GA.(eds): Principles of Bone Biology, second edition. San Diego, Academic Press, 2002, pp 961

97. Pilbeam CC, Harrison JR, Raisz LG: Principles of Bone Biology, second edition. San Diego, Academic Press, 2002, pp 979

97a. Krebs LJ, Arnold A. Molecular basis of hyperparathyroidism and potential targets for drug development. Curr. Drug Targets Immune Endocr Metabol Disord. 2:167, 2002.

97b. Carpten JD, Robbins CM, Villablanca A et al. HRPT2 encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genet. 32:676, 2002.

97c. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo L-O, Larsson C, Arnold A. Somatic and germline mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 349:1722-9, 2003.

97d. Kifor O, Moore, FD, Delaney M et al. A syndrome of hypocalciuric hypercalcemia caused by antibodies directed against the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88:60-72, 2003.

98. Agarwal A, Mishra SK, Gujral RB: Advanced skeletal manifestations in primary hyperparathyroidism. Can.J.Surg. 41: 342 1998

99. Bandeira F, Griz L, Caldas G, et al: Characteristics of primary hyperparathyroidism in one institution in northeast Brazil. Bone: 5:S380 1998

100. Biyabani SR, Talati J: Bone and renal stone disease in patients operated for primary hyperparathyroidism in Pakistan: Is the pattern of disease different from the west? J.Pakistan Med.Assoc. 49:194 1999

101. Chan TB, Lee KO, Rauff A, et al: Primary hyperparathyroidism at the Singapore general hospital. Singapore Med.J. 27:154 1986

102. Harinarayan CV, Gupta N, Kochupillai N: Vitamin D status in primary hyperparathyroidism in India. Clin.Endocrinol. 43:351 1995

103. Silverberg SJ, Shane E, De LaCruz L, et al: Skeletal disease in primary hyperparathyroidism. J.Bone Miner.Res. 4:283 1989

104. Silverberg, SJ, Shane E, Jacobs TP, et al: Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am.J.Med. 89:327 1990

105. Silverberg, SJ, Shane E, Jacobs TP, et al: The natural history of treated and untreated asymptomatic primary hyperparathyroidism: A ten year prospective study. N.Engl.J.Med. 341:1249 1999

106. Fitzpatrick LA, Bilezikian JP: Acute primary hyperparathyroidism. Am.J.Med. 82:275 1987

107. Gallagher JC, Nordin BEC: Treatment with oestrogens of primary hyperparathyroidism in postmenopausal women. Lancet 1:503 1972

108. Adami S, Mian M, Bertoldo F, et al: Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: Effects of bisphosphonate treatment. Clin.Endocrinol. 33:391 1990

109. Silverberg SJ, Bone HG III, Marriott TB, et al: Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N.Eng.J.Med. 337:1506 1997

110. Proceedings of the NIH Consensus Development Conference on diagnosis and management of asymptomatic primary hyperparathyroidism. J.Bone Miner.Res. Suppl2:S1 1991

111. Wermer P: Genetic aspects of adenomatosis of endocrine glands. Am.J.Med. 16:363 1954

112. Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia type 1. Science 276:404 1997

113. Marx SJ: Multiple endocrine neoplasia type I., in Bilezikian JP, Marcus R, Levine MA. (eds): The parathyroids: basic and clinical concepts, second edition. San Diego, Academic Press, 2001, pp 535

114. Sipple JH: The association of pheochromocytoma with carcinoma of the thyroid gland. Am.J.Med. 31:163 1961

115. Gagel RF: Multiple endocrine neoplasia., in Wilson JD, Foster DW, Larsen PR, et al. (eds): Williams textbook of endocrinology, 9th edition. Philadelphia, Saunders, 1997, pp 1627

116. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458 1993

117. Carney JA, Go VL, Sizemore GW, et al: Alimentary-tract ganglioneuromatosis. A major component of the syndrome of multiple endocrine neoplasia, type 2b. N.Engl.J.Med. 295:1287 1976

118. Mulligan LM, Eng C, Attie T, et al: Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Hum.Mol.Genet. 3:2163 1994

119. Mallette LE, Malini S, Rappaport MP, et al: Familial cystic parathyroid adenomatosis. Ann.Intern.Med. 107:54 1987

120. Jackson CE, Norman RA, Boyd SB, et al: Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: A clinically and genetically distinct syndrome. Surgery 108:1006 1990

121. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 89:96-102, 2004.

122. Marx SJ, Attie MF, Levine MA, et al: The hypocalciuric or benign variant of familial hypercalcemia: Clinical and biochemical features in fifteen kindreds. Medicine 60:397 1981

123. Heath H III: Familial benign (Hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. Endocrinol.Metab.Clin.North Am. 18:723 1989

124. Pollak MR, Brown EM, Chou YH, et al: Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75:1297 1993

125. Marx SJ, Attie MF, Spiegel AM, et al: An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. N.Eng.J.Med. 306:257 1982

126. Parfitt AM: Parathyroid growth: normal and abnormal., in Bilezikian JP, Marcus R, Levine MA. (eds): The parathyroids: basic and clinical concepts, second edition. San Diego, Academic press, 2001, pp 293

127. Burman KD, Monchick JM, Earl JM, et al: Ionized and total serum calcium and parathyroid hormone in hyperthyroidism. Ann.Intern.Med. 84:668 1976

128. Britto JM, Fenton AJ, Holloway WR, et al: Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 123:169 1994

129. Rosen HN, Moses AC Gundberg C, et al: Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans. J.Clin.Endocrinol.Metab. 77:664 1993

130. Rude RK, Oldham SB, Singer FR, et al: Treatment of thyrotoxic hypercalcemia with propranolol. N.Eng.J.Med. 294:431 1976

131. Ross DS, Nussbaum SR: Reciprocal changes in parathyroid hormone and thyroid function after radioiodine treatment of hyperthyroidism. J.Clin.Endocrinol.Metab. 68:1216 1989

132. Vasikaran SD, Tallis GA, Braund WJ: Secondary hypoadrenalism presenting with hypercalcaemia. Clin.Endocrinol. 41:261 1994

133. Diamond T, Thornley S: Addisonian crisis and hypercalcaemia. Aust.N.Z.J.Med. 24:316 1994

134. Schipiani E, Kruse K, Jhppner H: A constitutively active mutant PTH-PTHrp receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98 1995

135. Zondek H, Petrow H, Siebert W: Die Bedeutung der Calciumbestimmung im Blute fhr die Diagnose der Niereninsuffizienz. Z.Klin.Med. 9:129 1924

136. Gutman Ab, Tyson TL, Gutman EB: Serum calcium, inorganic phosphorus, and phosphatase activity in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic disease of bones. Arch.Int.Med. 7:379 1936

137. Albright R: Case records of the Massachusetts General Hospital (Case 27401). N.Engl.J.Med. 225:789 1941

138. Lafferty FW: Pseudohyperparathyroidism. Medicine 45:247 1966

139. Powell D, Singer FR, Murray TM, et al: Non-parathyroid humoral hypercalcemia in patients with neoplastic disease. N.Engl.J.Med. 89: 176 1973

140. Simpson EL, Mundy GR, D'Souza SM, et al: Absence of parathyroid hormone messenger RNA in non-parathyroid tumors associated with hypercalcemia. N.Engl.J.Med. 309:325 1983

141. Goltzman D, Stewart AF, Broadus AE: Malignancy-associated hypercalcemia evaluation with a cytochemical bioassay for parathyroid hormone. J.Clin.Endocrinol.Metab. 53:899 1981

142. Stewart AF, Insogna KL, Goltzman D, et al: Identification of adenylate cyclase-stimulating activity and cytochemical glucose-6-phosphatedehydrogenase-stimulating activity in extracts of tumours from patients with hypercalcemia of malignancy. Proc.Natl.Acad.Sci.USA. 80:1454 1983

143. Suva LJ, Winslow GA, Wettenhall REH, et al: A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 237:893 1987

144. Kukreja SC, Schavin DH, Winbuscus S, et al: Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy associated hypercalcemia due to human tumors. J.Clin.Invest. 82:1798 1988

145. Henderson JE, Bernier S, D'Amour P, et al: Effects of passive immunization against parathyroid hormone (PTH)-like peptide and PTH in hypercalcemic tumor-bearing rats and normocalcemic controls. Endocrinology 127:1310 1990

146. Fraher LJ, Hodsman AB, Jonas K, et al: A comparison of the in vivo biochemical responses to exogenous parathyroid hormone (1-34) [PTH 1-34] and PTH-related peptide (1-34) in man. J.Clin.Endocrinol.Metab. 75:417 1992

147. Yamato H, Nagai Y, Inoue D, et al: In vivo evidence for progressive activation of parathyroid hormone-related peptide gene transcription with tumor growth and stimulation of osteoblastic bone formation at an early stage of humoral hypercalcemia of malignancy. J.Bone Miner.Res. 10:36 1995

148. Budayr AA, Nissenson RA, Klein RF, et al: Increased serum levels of parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann.Intern.Med. 111:807 1989

149. Burtis WJ, Brady TG, Orloff JJ, et al: Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N.Eng.J.Med. 322:1106 1990

150. Henderson JE, Shustik C, Kremer R, et al: Circulating concentrations of parathyroid hormone-like peptide in malignancy and hyperparathyroidism. J.Bone Miner.Res. 5:105 1990

151. Ratcliffe WA, Norbury C, Stott RA, et al: Immunoreactivity of plasma parathyrin-related peptide: Three region specific radioimmunoassays and a two-site immunoradiometric assay compared. Clin.Chem. 37:1781 1991

152. Grill V, Ho P, Body JJ, et al: Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J.Clin.Endocrinol.Metab. 73:1309 1991

153. Holt EH, Vasavada R, Broadus AE, et al: Region-specific methylation of the PTH-related peptide gene determines its expression in human renal carcinoma lines. J.Biol.Chem. 268:20639 1993

154. Sidler B, Alpert L, Henderson JE, et al: Overexpression of parathyroid hormone-related peptide (PTHrP) by gene amplification in colonic carcinoma. J.Clin.Endocrinol.Metab. 81:2841 1996

154a Truong NU, deB Edwardes MD, Papavasiliou V, et al:  Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med. 115:115  2003

155. Nakayama K, Fukumoto S, Takeda S, et al: Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J.Clin.Endocrinol.Metab.81:607 1996

156. Stewart AF, Vignery A, Silvergate A, et al: Quantitative bone histomorphometry in humoral hypercalcemia of malignancy. J.Clin.Endocrinol.Metab. 55:219 1982

157. Guise TA, Yin JJ, Taylor SD, et al: Evidence for a causal role of parathyroid hormone related protein in the pathogenesis of human breast cancer-mediated osteolysis. J.Clin.Invest. 98:1544 1996

158. Rabbani SA, Gladu J, Harakidas P, et al: Overproduction of parathyroid hormone related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int.J.Cancer 80:257 1999

159. Yin JJ, Selander K, Chirgwin JM, et al: TGF-b signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J.Clin.Invest. 103:197 1999

160. Kremer R, Shustik C, Tabak T, et al: Parathyroid hormone related peptide in hematologic malignancies. Am.J.Med. 100406 1996

161. Firkin F, Seymour JF, Watson AM, et al: Parathyroid hormone related protein in hypercalcemia associated with haematological malignancy. Br.J.Haematol. 94:486 1996

162. Watanabe T, Yamaguchi K, Takatsuki K, et al: Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemic virus type I (HTLV1) carriers and adult T cell leukemic patients that can be transactivated by HTLV-1 tax gene. J.Exp.Med. 172:759 1990

163. Grill V, Murray RML, Ho PWM, et al: Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with pamidronate disodium (APD). J.Clin.Endocrinol.Metab. 74:468 1992

163a. Truong NU, de B Edwardes MD, Papavasiliou V, Goltzman D, Kremer R. Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am. J Med. 115:115, 2003.

164. Breslau NA, McGuire JL, Zerwekh JE, et al: Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma. Ann.Intern.Med. 100:1 1984

165. Rosenthal NR, Insogna KL, Godsall JW, et al: Elevations in circulating 1,25(OH)2D in three patients with lymphoma-associated hypercalcemia. J.Clin.Endocrinol.Metab. 60:29 1985

166. Seymour JF, Gagel RF, Hagemeister FB, et al: Calcitriol production in hypercalcemia and normocalcemia patients with non-Hodgkin lymphoma. Ann.Intern.Med. 121:633 1994

167. Nagai M, Kyakumoto S, Sato N: Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem.Biophys.Res.Commun. 269:532 2000.

168. Nagai Y, Yamamoto H, Akaogi K, et al: Role of interleukin-6 in uncoupling of bone in vivo in a human squamous carcinoma coproducing parathyroid hormone-related peptide and interleukin-6. J.Bone Miner.Res. 13:664 1998

169. Nussbaum SR, Gaz RD, Arnold A: Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for PTH. N.Engl.J.Med. 323:1324 1990

170. Iguchi H, Miyagi C, Tomita K, et al: Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland. J.Clin.Endocrinol.Metab. 83:2653 1998

171. Mundy GR, Yoneda T, Guise TA, et al: Local factors in skeletal malignancy., in Bilezikian JP, Raisz LJ, Rodan GA. (eds): Principles of Bone Biology, second edition. San Diego, Academic Press, 2002, pp 1093

171b. Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci USA 98:11581, 2001.

171c Tian E, Zhan F, Walker R, et al:. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 349: 2483 2003

172. Adams JS: Hypercalcemia due to granuloma-forming disorders., in Favus MJ. (ed): Primer on the metabolic bone diseases and disorders of mineral metabolism, fourth edition. Philadelphia, Lippincott, Williams and Wilkins, 1999, pp 212

173. Studdy PR, Bird R, Neville E, et al: Biochemical findings in sarcoidosis. J.Clin.Pathol. 33:528 1980

174. Bell NH, Gill JR Jr, Bartter FC: On the abnormal calcium absorption in sarcoidosis: evidence for increased sensitivity to vitamin D. Am.J.Med. 36:500 1964

175. Fallon MD, Perry HM III, Teitelbaum SL: Skeletal sarcoidosis with osteopenia. Metab.Bone Dis.Res. 3:171 1981

176. Rizzato G, Montemurro L, Fraioli P: Bone mineral content in sarcoidosis. Semin.Resp.Med. 13:411 1992

177. Adams JS, Singer FR, Gacad MA, et al: Isolation and structural identification of 1,25-dihydroxyvitamin D3 produced by cultured alveolar macrophages in sarcoidosis. J.Clin.Endocrinol.Metab. 60:960 1985

178. Sandler LM, Wineals CG, Fraher LJ, et al: Studies of the hypercalcaemia of sarcoidosis: effects of steroids and exogenous vitamin D3 on the circulating concentration of 1,25-dihydroxyvitamin D3. Q.J.Med. 53:165 1984

179. Adams JS, Diz MM, Sharma OP: Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann.Intern.Med. 111:437 1989

180. Adams JS, Sharma OP, Diz MM, et al: Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J.Clin.Endocrinol.Metab. 70:1090 1990

181. Zaloga GP, Chernow B, Eil C: Hypercalcemia and disseminated cyto-megalovirus infection in the acquired immunodeficiency syndrome. Ann.Int.Med. 102:331 1985

182. Gayet S, Ville E, Durand JM, et al: Foscarnet-induced hypercalcemia in AIDS. AIDS 11:1068 1997

183. Preus M: The Williams syndrome: objective definition and diagnosis. Clin.Genet. 25:422 1984

184. Taylor AB, Stern PH, Bell NH: Abnormal regulation of circulating 25OHD in the Williams syndrome. N.Engl.J.Med. 306:972 1982

185. Curran ME, Atkinson DL, Ewart AK, et al: The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell 73:159 1993

186. Martin NDT, Snodgrass GJAI, Cohen RD: Idiopathic infantile hypercalcemia: a continuing enigma. Arch.Dis.Child. 59:605 1984

187. Porter RH, Cox BG, Heaney D, et al: Treatment of hypoparathyroid patients with chlorthalidone. N.Engl.J.Med. 298:577 1978

188. Haden ST, Stoll AL, McCormick S, et al: alterations in parathyroid dynamics in lithium-treated subjects. J.Clin.Endocrinol.Metab. 82:2844 1979

189. Pettifor JM, Bikle DD, Cavalerso M, et al: Serum levels of free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann.Intern.Med. 122:511 1995

190. Valente JD, Elias AN, Weinstein GD: Hypercalcemia associated with oral isotretinoin in the treatment of severe acne. JAMA 290:1899 1983

191. Suzumiya J, Asahara F, Katakami H, et al: Hypercalcemia caused by all trans-retinoic acid treatment of acute promyelocytic leukaemia: case report. Eur.J.Haematol. 53:126 1994

192. Villablanca J, Khan AA, Avramis VI, et al: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J.Clin.Oncol. 13:894 1995

193. Legha SS, Powell K, Buzdar AU, et al: Tamoxifen-induced hypercalcemia in breast cancer. Cancer 47:2803 1981

194. Ott SM, Maloney NA, Klein GL, et al: Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann.Intern.Med. 96:910 1983

195. Beall DP, Scofield RH: Milk-alkali syndrome associated with calcium carbonate consumption. Medicine 74: 89 1995

196. Nussbaum Sr, Zahradnik RK, Lavigne JR, et al: Highly sensitive two-site immunoradiometric: assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin.Chem. 33:1364 1987

197. Wei JP, Burke GJ: Cost utility of routine imaging with Tc-99m-sestamibi in primary hyperthyroidism before initial surgery. Amer.Surg. 63(12):1097 1997

198. Miccoli P, Bendinelli C, Vignali E, et al: Endoscopic parathyroidectomy: Report of an initial experience. Surgery 124:1077 1998

199. Chen H, Sokoll LJ, Udelsman R: Outpatient minimally invasive parathyroidectomy: A combination of sestamibi-SPECT localization, cervical block anesthesia, and intraoperative parathyroid hormone assay. Surgery 126:1016 1999

200. Hosking DJ, Cowley A, Bucknall CA: Rehydration in the treatment of severe hypercalcemia. QJ Med. 200:473 1981

201. Nussbaum SR, Younger J, VandePol CJ, et al: Single dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-60-, and 90 mg dosages. Am.J.Med. 95:297 1993

202. Body JJ, Lortholary A, Romieu G, et al: A dose-finding study of zoledronate in hypercalcemic cancer patients. J.Bone Miner.Res. 14:1557 1999

203. Silva O, Becker KL: Salmon calcitonin in the treatment of hypercalcemia. Arch.Intern.Med. 132:337 1973

204. Ralston SH, Alzaid AA, Gardner MD, et al: Treatment of cancer associated hypercalcemia with combined aminohydroxypropylidine diphosphonate and calcitonin. Br.Med.J. 292:1549 1986

205. Perlia CP, Gubisch NJ, Cootter J, et al: Mithramycin treatment of hypercalcemia. Cancer 25:389 1970

206. Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 341:1611 1993

207. Percival RC, Yates AJP, Gray RES, et al: The role of glucocorticoids in the management of malignant hypercalcemia. Br.Med.J. 289:287 1984

208. Heyburn PJ, Selby PL, Peacock M, et al: Peritoneal dialysis in the management of severe hypercalcaemia. Br.Med.J. 280:525 1980

209. Cardella CJ, Birkin BL, Rapoport A: Role of dialysis in the treatment of severe hypercalcemia: Report of two cases successfully treated with hemodialysis and review of the literature. Clin.Nephrol. 12:285 1979

210. Bergstrom WH: Hypercalciuria and hypercalcemia complicating immobilization. Am.J.Dis.Child. 132:553 1978

211. McIntyre HD, Cameron DP, Urquhart SM, et al: Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad.Med.J. 65:244 1989